40655-37-6

Basic information

• Product Name: N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide
• Synonyms: N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide;N-(2-Nitro-4-tert-butylphenyl)acetamide
• CAS NO: 40655-37-6
• Molecular Formula: C₁₂H₁₆N₂O₃
• Molecular Weight: 236.26704
• EINECS: 255-023-0
• Mol File: 40655-37-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 385.2 °C at 760 mmHg
• Flash Point: 186.8 °C
• Appearance: /
• Density: 1.175 g/cm³
• Vapor Pressure: 3.87E-06mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide(40655-37-6)
• EPA Substance Registry System: N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide(40655-37-6)

Safety Data

• Hazardous Substances Data: 40655-37-6(Hazardous Substances Data)

Usage

General Description

N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide, also referred to as 'BAY 73-6691', is a potent and selective inhibitor of the enzyme phosphodiesterase 9 (PDE9). N-[4-(1,1-dimethylethyl)-2-nitrophenyl]acetamide is particularly notable for its use in scientific research related to neurological disorders, including Alzheimer's disease. The inhibition of PDE9 by this chemical can lead to an increase in cyclic guanosine monophosphate (cGMP) within the brain which has potential therapeutic benefits in cognitive enhancement. Despite its promise, the chemical compound is still largely in the experimental stages of its development and use. BAY 73-6691 is not approved for any therapeutic indications and is currently not commercially available, it is only used for research purposes.

InChI:InChI=1/C12H16N2O3/c1-8(15)13-10-6-5-9(12(2,3)4)7-11(10)14(16)17/h5-7H,1-4H3,(H,13,15)

Upstream product

• 103-84-4 Acetanilid 
• 769-92-6 4-tert-Butylaniline 
• 20330-45-4 4-tert-butylacetanilide 
• 108-24-7 acetic anhydride 
• 3282-56-2 4-tert-butylnitrobenzene 
• 253185-03-4 tert-butylbenzene 

Downstream Products

• 22503-15-7 N-(4-(tert-butyl)-2,6-dinitrophenyl)acetamide 
• 342045-14-1 2-amino-4-tert-butylacetanilide 
• 85020-95-7 4-t-butyl-N-methyl-2-nitroacetanilide 
• 1353014-56-8 7-benzyl-1,13-dibromo-3,11-di-tert-butyl-6H-benzamidazo[2',1':3,4]pyrrolo[3',4':5,6]-pyrazino[1,2-a]benzimidazole-6,8(7H)-dione 
• 1027356-55-3 2-bromo-4-tert-butyl-6-nitroaniline 
• 1449475-90-4 benzyl (3S)-3-(1-benzyl-5-tert-butyl-1H-benzimidazol-2-yl)-3-[(tert-butoxycarbonyl)-amino]propanoate 
• 1449475-91-5 N-1-benzyl-4-tert-butylbenzene-1,2-diamine 
• 1449475-92-6 (S)-benzyl-4-(2-benzylamino)-3-tert-butylphenylamino-3-(tert-butyxoycarbonylamino)-4-oxobutanoate 
• 1287738-87-7 3'-(5-tert-butyl-1H-benzo[d]imidazol-1-yl)biphenyl-2-carbonitrile 
• 159725-23-2 1-(3-bromophenyl)-5-tert-butyl-1H-benzo[d]imidazole 
• 159725-64-1 C₁₆H₁₉BrN₂ 
• 1287738-95-7 5'-(5-tert-butyl-1H-benzo[d]imidazol-1-yl)-2',6-difluorobiphenyl-2-carbonitrile 
• 1287739-91-6 5'-(4-tert-butyl-2-nitrophenylamino)-2',6-difluorobiphenyl-2-carbonitrile 
• 159724-47-7 N-(3-bromophenyl)-4-tert-butyl-2-nitroaniline 

Relevant articles and documents

Transition-metal-free mono- or dinitration of protected anilines

An amide-assisted arene nitration is presented, and both mono- and dinitration of protected anilines could be effected by using NaNO2 and NaNO3 as the mono- and bisnitrating agents, respectively. This divergent synthesis is transition-metal- and acid-free, and features a broad substrate scope, low cost, and ortho–para selectivity.

BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS

The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7. X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.

SUBSITITUTED BENZIMIDAZOLES

This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates theGABAA receptor. This invention also provides novel intermediates for the preparation of the compounds of the invention, and salts thereof.